Nova Pharmaceuticals Australasia Pharmaceutical Import Profile — Australia (DGFT 2022–2026)

Name: Nova Pharmaceuticals Australasia Pharmaceutical Import Records from India — 2 Products, $560.4K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Nova Pharmaceuticals Australasia — Pharmaceutical Importer Profile (2026) | 2 Products, $560.4K Trade | TransData Nexus

Nova Pharmaceuticals Australasia

Pharmaceutical Importer · Australia · Analgesics & Antipyretics Focus · $560.4K Total Trade · DGFT Verified

Nova Pharmaceuticals Australasia is a pharmaceutical importer based in Australia with a total trade value of $560.4K across 2 products in 2 therapeutic categories. Based on 64 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Nova Pharmaceuticals Australasia sources from 8 verified Indian suppliers, with Marksans Pharma Limited accounting for 60.9% of imports.

Nova Pharmaceuticals Australasia — Import Portfolio & Supplier Network

Nova Pharmaceuticals Australasia import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Nova Pharmaceuticals Australasia?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Marksans Pharma Limited	$12.7M	665	60.9%
V S International Private Limited	$4.1M	221	19.9%
Mepro Pharmaceuticals Private Limited

What Formulations Does Nova Pharmaceuticals Australasia Import?

Formulation	Value	Ships
Ibuprofen soft gelatin capsules 200 MG	$692.3K	19
Ibuprofen round shaped tabs BP 200MG	$590.3K	16
Anaesthetic lozenges - betadine	$558.7K	14
Paracetamol TAB BP 500MG rapid release	$380.0K	25
Paracetamol tablets BP 500MG batch no	$247.2K	14
Coles ibuprofen tablets 200 MG	$247.0K	6
Paracetamol tablets 500MG batch no	$244.1K	6
Ibuprofen round shaped tabs BP 200MG	$234.4K	7
Hedafen ibuprofen round shaped tablets 200 MG	$193.9K	6
Paracetamol and caffeine TAB 500/65 MG	$176.4K	13
Anaesthetic lozenges - betadine	$164.6K	4
Paracetamol capsules 500MG batch no	$156.5K	7
Paracetamol capsules 500MG batch no	$155.1K	6
Ibuprofen softgelatin CAPS 200 MG	$147.6K	8
Pharmaceutical products apohealth	$136.8K	4

Nova Pharmaceuticals Australasia imports 619 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Aspirin	Analgesics & Antipyretics	$411.9K	49	1.1%	17
2	Melatonin	Nutritional Supplements	$148.5K	15	1.6%	15

Nova Pharmaceuticals Australasia imports 2 pharmaceutical products across 2 categories into Australia totaling $560.4K.

Nova Pharmaceuticals Australasia — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Nova Pharmaceuticals Australasia Pty Ltd, established in 2003 in Sydney, Australia, is a privately owned, innovative pharmaceutical company. Over the past two decades, it has become a leading supplier of medicinal products to Australian pharmacies and supermarkets, including major chains such as Coles, Woolworths, Aldi, and Metcash. The company offers a broad and diverse portfolio, encompassing both prescription and over-the-counter (OTC) medications. In 2019, Nova Pharmaceuticals expanded into the pharmacy sector with its own product range, now available in 3,885 pharmacies nationwide, positioning itself as one of the fastest-growing pharmaceutical companies in Australia's OTC category. (novapharm.com.au)

Strategic partnerships with industry leaders like Sanofi and Arrotex have bolstered Nova Pharmaceuticals' market presence. The company's key brands include Glucoboost, Bubs & Co, Elactalyte, and MediChoice Eucalyptus Spray. These products are distributed through all pharmacy wholesalers in Australia and are supported by major pharmacy groups. Nova Pharmaceuticals' vision is to make a meaningful difference in people's lives by providing access to quality medicine at affordable prices, underpinned by values of respect, integrity, and trust. (novapharm.com.au)

2Distribution Network

Nova Pharmaceuticals' distribution network is centered in Bella Vista, New South Wales, where its headquarters are located. The company has established a robust logistics infrastructure to support its nationwide operations, ensuring efficient supply chain management and timely delivery of products across Australia. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, Nova Pharmaceuticals' extensive reach across Australian pharmacies and supermarkets indicates a well-developed distribution system capable of meeting the demands of the market. (novapharm.com.au)

3Industry Role

Nova Pharmaceuticals Australasia operates primarily as a pharmaceutical importer and distributor within Australia's supply chain. By sourcing a diverse range of medicinal products, including both prescription and OTC medications, the company plays a pivotal role in ensuring the availability of essential medicines to Australian consumers. Its strategic partnerships with global pharmaceutical manufacturers and its own product range underscore its significant position in the market. (novapharm.com.au)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Nova Pharmaceuticals Australasia

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Nova Pharmaceuticals Australasia's sourcing strategy exhibits a high degree of concentration, with a total import value of $560,000 USD from India across 64 shipments, primarily consisting of finished pharmaceutical formulations. The top five imported products—Aspirin and Melatonin—account for 100% of the company's imports from India, indicating a focused product portfolio. This concentration suggests a strategic choice to specialize in specific therapeutic areas, potentially allowing for optimized supply chain management and cost efficiencies. However, such dependency on a limited number of products and suppliers may pose risks related to supply chain disruptions or changes in market demand.

2Supply Chain Resilience

The resilience of Nova Pharmaceuticals Australasia's supply chain is influenced by its reliance on a select group of Indian suppliers, including MARKSANS PHARMA LIMITED, V S INTERNATIONAL PRIVATE LIMITED, and MEPRO PHARMACEUTICALS PRIVATE LIMITED. While these partnerships may offer stability, the limited number of suppliers could expose the company to risks associated with geopolitical events, regulatory changes, or operational challenges in India. Diversifying the supplier base and incorporating additional backup suppliers could enhance supply chain resilience. Ensuring that all suppliers comply with international Good Manufacturing Practice (GMP) standards is crucial to maintain product quality and meet Australian regulatory requirements.

Importing Pharmaceuticals into Australia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Australia

1Regulatory Authority & Framework

In Australia, the Therapeutic Goods Administration (TGA) is the primary regulatory body responsible for overseeing the safety, efficacy, and quality of therapeutic goods, including pharmaceuticals. The TGA operates under the Therapeutic Goods Administration Act 1989, which outlines the regulatory framework for the importation, manufacturing, and distribution of therapeutic goods in Australia. To legally import therapeutic goods, they must be entered in the Australian Register of Therapeutic Goods (ARTG), unless exempt. The TGA's role encompasses evaluating and approving medicines, ensuring compliance with manufacturing standards, and monitoring the supply chain to protect public health. (tga.gov.au)

2Import Licensing & GMP

Importers of therapeutic goods into Australia must comply with specific licensing requirements set by the TGA. Generally, therapeutic goods must be entered in the ARTG before they can be legally imported, unless they are exempt. Importers are responsible for ensuring that all imported products meet the TGA's standards for quality, safety, and efficacy. Manufacturers of these goods must hold a valid GMP certificate recognized by the TGA, such as EU GMP, WHO GMP, or PIC/S certifications. Additionally, importers must obtain wholesale distribution authorization to supply therapeutic goods within Australia. (tga.gov.au)

Nova Pharmaceuticals Australasia — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Nova Pharmaceuticals Australasia's focus on importing analgesics and antipyretics, such as Aspirin, and nutritional supplements, like Melatonin, aligns with market demand for over-the-counter products that address common health concerns. The company's strategic emphasis on these therapeutic areas allows it to cater to a broad consumer base seeking accessible and affordable health solutions. By concentrating on high-demand products, Nova Pharmaceuticals can leverage economies of scale and strengthen its market position in the Australian pharmaceutical sector.

2Sourcing Profile

Nova Pharmaceuticals Australasia's sourcing strategy is centered on importing finished pharmaceutical formulations from India, focusing on generic drugs. This approach enables the company to offer cost-effective alternatives to branded medications, making essential health products more accessible to Australian consumers. India's well-established pharmaceutical manufacturing industry, with its adherence to international GMP standards, complements Nova Pharmaceuticals' procurement strategy, ensuring a reliable supply of quality products.

3Market Positioning

Seller's Guide — How to Become a Supplier to Nova Pharmaceuticals Australasia

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Nova Pharmaceuticals Australasia, particularly if they can offer high-quality products that meet Australian regulatory standards. Gaps in Nova Pharmaceuticals' current sourcing may exist in therapeutic areas not currently covered, presenting potential avenues for expansion. Establishing a partnership would require demonstrating product quality, compliance with GMP standards, and an understanding of the Australian market dynamics.

2Requirements & Qualifications

Indian exporters seeking to supply Nova Pharmaceuticals Australasia must ensure their products are registered in the ARTG and comply with Australian labeling and packaging requirements. Manufacturers must hold valid GMP certifications recognized by the TGA, such as EU GMP, WHO GMP, or PIC/S. Additionally, exporters should be prepared to provide detailed product dossiers and undergo audits as part of the import approval process. (tga.gov.au)

3How to Approach

Frequently Asked Questions — Nova Pharmaceuticals Australasia

What products does Nova Pharmaceuticals Australasia import from India?

Nova Pharmaceuticals Australasia imports 2 pharmaceutical products across 2 categories. Top imports: Aspirin ($411.9K), Melatonin ($148.5K).

Who supplies pharmaceuticals to Nova Pharmaceuticals Australasia from India?

Nova Pharmaceuticals Australasia sources from 8 verified Indian suppliers. The primary supplier is Marksans Pharma Limited (60.9% of imports, $12.7M).

What is Nova Pharmaceuticals Australasia's total pharmaceutical import value?

Nova Pharmaceuticals Australasia's total pharmaceutical import value from India is $560.4K, based on 64 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Nova Pharmaceuticals Australasia focus on?

Nova Pharmaceuticals Australasia imports across 2 categories. The largest: Analgesics & Antipyretics (73.5%), Nutritional Supplements (26.5%).

Get Full Nova Pharmaceuticals Australasia Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.